Receptores hormonales y de estrógenos en la mujer transexual (página 2)

13. Dehm SM, Tindall DJ: Androgen
receptor structural and functional elements: role and
regulation in prostate cancer. Mol Endocrinol 2007,
21:2855-2863.

14. Denton RR, Notides AC.
Estrogen receptor phosphorylation. Hormonal dependence and
consequence on specific DNA binding. J Biol Chem
1992;267:7263–7268•

15. Díaz, B. N. 2004.
Bioquímica Básica de las Hormonas Esteroideas:
Biología y Clínica del Cáncer.
Biocáncer 2. pp 1-22.

16.  Diez-Perez A. Selective
estrogen receptor moduladors(SERMS).Arq Bras Endocrinol Metab
2006;50:720-734.

17. Enmark E, Pelto-Huikko M,
Grandien K, Lagercrantz S, Lagercrantz J, Fried G,
Nordenskjold M & Gustafsson JA 1997 Human estrogen
receptor beta-gene structure, chromosomal localization, and
expression pattern.Journal of Clinical Endocrinology and
Metabolism824258–4265

18. Fuqua SA, Schiff R, Parra I,
Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB,
Willson TM, Moore JT. Expression of wild-type estrogen
receptor beta and variant isoforms in human breast cancer.
Cancer Res 1999;59:5425-5428

19. Gelmann EP: Molecular biology
of the androgen receptor. J Clin Oncol 2002,
20:3001-3015.

20. Grossmann ME, Huang H, Tindall
DJ: Androgen receptor signaling in androgen-refractory
prostate cancer. J Natl Cancer Inst 2001,
93:1687-1697.

21. Gustafsson, J. A. 1999.
Estrogen receptor ßeta- a new dimension in estrogen
mechanism of action. Journal of Endocrinology. 163, 379
– 383.

22. Haelens A, Tanner T, Denayer
S, Callewaert L, Claessens F: The hinge region regulates DNA
binding, nuclear translocation, and transactivation of the
androgen receptor. Cancer Res 2007, 67:4514-4523.

23. Hart, S. M. 2002. Modulation
of nuclear receptor dependent transcription. Biol Res. 35:
295 – 303.

24. Heinlein CA, Chang C: Androgen
receptor (AR) coregulators: an overview. Endocr Rev 2002,
23:175-200.

25. Heinlein CA, Chang C: Androgen
receptor in prostate cancer. Endocr Rev 2004,
25:276-308

26. Herrera, E. 1991. Hormonas
Esteroideas, en: Bioquímica. Biología molecular
y bioquímica fisiológica, 2ª
edición, vol II. McGraw-Hill/ Interamericana.
España: 1161 – 1172.

27. Hillier SG, Anderson RA,
Williams AR, Tetsuka M. Expression of oestrogen receptor
alpha and beta in cultured human ovarian surface epithelial
cells. Mol Hum Reprod 1998;4:811-815

28.  Hsieh CL, Cai C, Giwa A et
al.: Expression of a hyperactive androgen receptor leads to
androgen-independent growth of prostate cancer cells. J Mol
Endocrinol 2008, 41:13-23.

29. Huch K.M., Elam, M.B.,
Chesney, C.M. Oral contraceptive Steroids induce
plateletcoagulant hyperactivity. Thromb.Res.1:41 -50,
1987

30. Katzung, B.
"Farmacología Básica y Clínica" 2ª
edic. 1986

31. Kingle, c. m. 2000. Estrogen
receptor interaction with co-activators and co-repressors.
Steroids. May; 65 (5): 227 – 251Madrid, España:
544 – 547 y 596 – 612.

32. Klein–Hitpass L, Ryffel
GU, Heitlinger E, Cato AC. A sindrome is a functional
estrogen responsive element and interacts specifically with
estrogen receptor. Nucleic Acids
Res1988;16:647–663.

33. Klinge CM. Estrogen receptor
interaction with estrogen response elements. Nucleic Acids
Research 2001;2905–2919•

34. Klinge CM. Estrogen receptor
interaction with co-activators and co-repressors. Steroid
2000;65:227-251•

35. Krishnan V, Heath H y Bryant
UH. Mechanism of action of estrogen and selective estrogen
receptors modulators. Vitamins and Hormones
2001;60:123-147

36. Kuiper GG, Enmark E,
Pelto-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of
a novel receptor expressed in rat prostate and ovary.PNAS93
5925–5930

37. Kumar R, Thompson EB.
Transactivation functions of the No-terminal domains of
nuclear hormone receptors: protein folding and coactivator
interactions. Mol Endocrinol 2003;17:1-10•

38. Luke MC, Coffey DS: The male
sex accessory tissues. Structure, androgen action, and
physiology. In The physiology of reproduction. Vol. 1 Edited
by Knobil E, Neill JD. Raven Press, New York;
1994:1435-1487.

39. Marin R, Guerra B, Alonso R,
Ramirez CM, Diaz M. Estrogen activates classical and
alternative mechanisms to orchestrate neuroprotection. Curr
Neurovasc Res 2005; 2(4): 287-301.

40. Mathews, c. k., van holde,
K.E. 1999. Mecanismo de Acción Hormonal, en:
Bioquímica, segunda edición.
McGraw-Hill/Interamericana. España: 918 –
939.

41. Mathews, c. k., van holde,
k.e. 1999. Metabolismo de los Esteroides, en:
Bioquímica, segunda edición.
McGraw-Hill/Interamericana. España: 749 –
760

42. Matsumoto T, Takeyama K, Sato
T, Kato S: Study of androgen receptor functions by genetic
models. J Biochem 2005, 138:105-110.

43. Montgomery r., Conway t. w.,
Spector a. a., chappell D. 1998. Endocrinología
Molecular: Señalización Celular mediante
Hormonas y Neurotransmisores. Hormonas que actúan en
el Interior de la Célula, en: Bioquímica, casos
y texto, sexta edición. Harcourt-Brace,

44. Olefsky, J.M. 2001. Nuclear
receptor minireview series. J. Biol. Chem. 276 (40): 36863
– 4.

45. Paech K, Webb P, Kuiper GG,
Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS 1997
Differential ligand activation of estrogen receptors ER alpha
and ERbeta at AP1 sites.Science2771508–1510.

46. Pelletier G & El-Alfy M
2000 Immunocytochemical localization of estrogen receptors
alpha and beta in the human reproductive organs.Journal of
Clinical Endocrinology and
Metabolism854835–4840

47. Revankar CM, Cimino CF, Sklar
LA, Arteburn JB, Prossnitz ER. A trans-membrane intracellular
estrogen receptor mediates rapid cell signaling. Science
2005; 307(5715): 1625-1630.

48. Reyes-Fuentes, A. and
Veldhuis, J D 1993. Neuroendocrine physiology of the normal
male gonadal axis. In Endocrinology and Metabolism Clinics of
North America. Edited by Velduis, J D Philadelphia, PA: W.B.
Saunders Co., 22:93-124

49. Shi Y, Downes M, Xie W, Kao
HY, Ordentlich P, Tsai CC, Hon M, Evans RM. Sharp, an
inducible cofactor that integrates nuclear receptor
repression and activation. Genes and Development
2001;15:1140–1151

50. So AI, Hurtado-Coll A, Gleave
ME: Androgens and prostate cancer. World J Urol 2003,
21:325-337.

51. Suzuki H, Ueda T, Ichikawa T,
Ito H: Androgen receptor involvement in the progression of
prostate cancer. Endocr Relat Cancer 2003,
10:209-216.

52. Taplin ME, Ho SM: Clinical
review 134: The endocrinology of prostate cancer. J Clin
Endocrinol Metab 2001, 86:3467-3477.

53. Tzukerman MT, Esty A,
Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW,
McDonnell DP. Human estrogen receptor transactivational
capacity is determined by both cellular and promoter context
and mediated by two functionally distinct intramolecular
regions. Mol Endocrinol. 1994;8:21–30•

54. Weigel NL, Moore NL: Steroid
receptor phosphorylation: a key modulator of multiple
receptor functions. Mol Endocrinol 2007,
21:2311-2319.

55. Weigel NL, Zhang Y.
Ligand-independent activation of steroid hormone receptors. J
Mol Med 1998;76:469-479•

56. Williams, Textbook of
Endocrinology, 8th edition. Edited by Wilson, J D and Foster,
D W Philadelphia, PA: W B Saunders Co., 978 – 995,
1992.

57. Wise PM, Dubal DB, Rau SW,
Brown CM, Suzuki S. Are estrogens protective or risk factors
in brain injury and neuro degeneration? Reevaluation after
the women"s health initiative. Endosc Rev 2005; 26(3):
308-312.

58. Wyllie AH, Kerr JF, Currie AR.
Cell death: the significance of apoptosis. Int Rev Cytol
1980;68:251-306.

59. Xing N, Chen Y, Mitchell SH,
Young CY: Quercetin inhibits the expression and function of
the androgen receptor in LNCaP prostate cancer cells.
Carcinogenesis 2001, 22:409-414.

60. Zhu ML, Kyprianou N: Androgen
receptor and growth factor signaling cross-talk in prostate
cancer cells. Endocr Relat Cancer 2008,
15:841-849.